Cargando…
The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559572/ http://dx.doi.org/10.1186/1532-429X-15-S1-O94 |
| _version_ | 1782257609186738176 |
|---|---|
| author | Kotwinski, Paul Smith, Gillian Sanders, Julie Ma, Louise Cooper, Jackie Thomas, Michael Mythen, Michael (Monty) G Jones, Alison Montgomery, Hugh E Pennell, Dudley J |
| author_facet | Kotwinski, Paul Smith, Gillian Sanders, Julie Ma, Louise Cooper, Jackie Thomas, Michael Mythen, Michael (Monty) G Jones, Alison Montgomery, Hugh E Pennell, Dudley J |
| author_sort | Kotwinski, Paul |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3559572 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-35595722013-02-01 The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity Kotwinski, Paul Smith, Gillian Sanders, Julie Ma, Louise Cooper, Jackie Thomas, Michael Mythen, Michael (Monty) G Jones, Alison Montgomery, Hugh E Pennell, Dudley J J Cardiovasc Magn Reson Oral Presentation BioMed Central 2013-01-30 /pmc/articles/PMC3559572/ http://dx.doi.org/10.1186/1532-429X-15-S1-O94 Text en Copyright ©2013 Kotwinski et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Kotwinski, Paul Smith, Gillian Sanders, Julie Ma, Louise Cooper, Jackie Thomas, Michael Mythen, Michael (Monty) G Jones, Alison Montgomery, Hugh E Pennell, Dudley J The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title | The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title_full | The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title_fullStr | The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title_full_unstemmed | The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title_short | The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity |
| title_sort | breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (better-care) study: cmr with early gadolinium relative enhancement, but not high-sensitivity troponin t, predicts the risk of chronic anthracycline cardiotoxicity |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559572/ http://dx.doi.org/10.1186/1532-429X-15-S1-O94 |
| work_keys_str_mv | AT kotwinskipaul thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT smithgillian thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT sandersjulie thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT malouise thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT cooperjackie thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT thomasmichael thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT mythenmichaelmontyg thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT jonesalison thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT montgomeryhughe thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT pennelldudleyj thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT kotwinskipaul breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT smithgillian breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT sandersjulie breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT malouise breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT cooperjackie breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT thomasmichael breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT mythenmichaelmontyg breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT jonesalison breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT montgomeryhughe breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity AT pennelldudleyj breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity |